DK2606120T3 - Humane faciliterende celler og anvendelser deraf. - Google Patents

Humane faciliterende celler og anvendelser deraf. Download PDF

Info

Publication number
DK2606120T3
DK2606120T3 DK11818739.2T DK11818739T DK2606120T3 DK 2606120 T3 DK2606120 T3 DK 2606120T3 DK 11818739 T DK11818739 T DK 11818739T DK 2606120 T3 DK2606120 T3 DK 2606120T3
Authority
DK
Denmark
Prior art keywords
cells
recipient
hfcs
donor
alpha
Prior art date
Application number
DK11818739.2T
Other languages
English (en)
Inventor
Suzanne Ildstad
Mary Jane Elliott
Original Assignee
Univ Louisville Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found filed Critical Univ Louisville Res Found
Application granted granted Critical
Publication of DK2606120T3 publication Critical patent/DK2606120T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)

Claims (15)

  1. - 1 -
    1. Terapeutisk cellulær sammensætning, der omfatter: 5 humane hæmatopoietiske stamceller (HSC’er), hvor HSC’eme har fænotypen CD34+; humane faciliterende celler (hFC’er), hvor hFC’eme omfatter celler med fænotypen CD8+ / alfa-beta-TCR- / CD56dim/neg og celler med fænotypen CD8+ / alfa-beta-TCR- / CD56bnght; og humane alfa-beta-TCR+-T-celler; 10 til anvendelse i en fremgangsmåde til at gøre immunsystemet hos en recipient kimerisk med immunsystemet hos en donor, hvilken fremgangsmåde omfatter: administrering af sammensætningen til recipienten, hvor recipienten er blevet konditioneret, hvor konditioneringen er helkropsbestråling, administration af et toksisk eller terapeutisk middel, administration af et monoklonalt antistof eller et monoklonalt 15 antistof, der er bundet til et toksin eller en radioisotop, eller en kombination af hvilke som helst af disse, hvor alfa-beta-TCR+-T-celleme er til stede i en mængde, der er større end, hvad der ville blive betragtet som terapeutisk, hvor antallet af alfa-beta-TCR+-T-celler er justeret til mellem 2,0 x 106 og 5,0 x 106 alfa-beta-TCR+-T-celler pr. kg af recipientens kropsvægt. 20
  2. 2. Sammensætning til anvendelse ifølge krav 1, hvor hFC’eme forbedrer inkorporeringsevnen for HSC’eme sammenlignet med HSC’er, der inkorporeres i fravær af hFC’eme.
  3. 3. Sammensætning til anvendelse ifølge krav 1, hvor konditioneringen af recipienten inkluderer en dosis af helkropsbestråling (TBI), hvor helkropsbestrålingen ikke overstiger 300 cGy.
  4. 4. Sammensætning til anvendelse ifølge krav 1, hvor den terapeutiske cellulære 30 sammensætning administreres til recipienten intravenøst. - 2 -
  5. 5. Sammensætning til anvendelse ifølge krav 1, hvor recipientens immunsystem betragtes som kimerisk med donorens immunsystem, når recipientens immunsystem er mindst 1 % donor-oprindelse.
  6. 6. Sammensætning til anvendelse ifølge krav 1, hvor recipienten har en sygdom, især hvor sygdommen er udvalgt fra gruppen, der består af: autoimmun sygdom, især diabetes, multipel sklerose eller systemisk lupus erythematosus, leukæmi, 10 en hæmoglobinopati, en arvelig metabolisk forstyrrelse, en sygdom, der nødvendiggør en organtransplantation, især hvor organet er hjerte, hud, lever, lunge, hjerte og lunge, nyre, pankreas, eller et endokrint organ, især hvor det endokrine organ er en thyreoideakirtel, parathyreoideakirtel, en thymus, binyrebark eller 15 binyremarv, en infektion af et immundefektvirus eller hepatitis og en hæmatopoietisk malignitet, anæmi, hæmoglobinopatier og en enzymdefekt.
  7. 7. Terapeutisk cellulær sammensætning til administration til en recipient, der omfatter: 20 humane hæmatopoietiske stamceller (HSC’er), hvor HSC’eme har fænotypen CD34+; humane faciliterende celler (hFC’er), hvor hFC’eme omfatter celler med fænotypen CD8+ / alfa-beta-TCR- / CD56dim/neg og celler med fænotypen CD8+ / alfa-beta-TCR- / CD56bnght; og humane alfa-beta-TCR+-T-celler, hvor alfa-beta-TCR+-T-celleme er til stede i en 25 mængde, der er større end, hvad der ville blive betragtet som terapeutisk, hvor antallet af alfa-beta-TCR+-T-celler er justeret til mellem 2,0 x 106 og 5,0 x 106 alfa-beta-TCR+-T-celler pr. kg af recipientens kropsvægt.
  8. 8. Sammensætning til anvendelse ifølge krav 1 eller sammensætning ifølge krav 7, hvor 30 antallet af alfa-beta-TCR+-T-celler er justeret til mellem 3,0 x 106 og 4,2 x 106 alfa- beta-TCR+-T-celler pr. kg af recipientens kropsvægt. - 3 -
  9. 9. Fremgangsmåde til fremstilling af en terapeutisk cellulær sammensætning til administration til en recipient, der omfatter trinene: tilvejebringelse afen donorkilde af humane hæmatopoietiske stamceller (HSC’er); udtømning af humane alfa-beta-TCR+-T-celler fra donorkilden til frembringelse af en 5 udtomt donorkilde; justering af antallet af humane alfa-beta-TCR+-T-celler i den udtømte donorkilde til mellem 2,0 x 106 og 5,0 x 106 humane alfa-beta-TCR+-T-celler pr. kg af recipientens kropsvægt, til derved frembringelse af en terapeutisk cellulær sammensætning til administration til 10 en recipient, hvor fremgangsmåden ikke benytter et humant embryo.
  10. 10. Fremgangsmåde ifølge krav 9, hvor kilden af humane HSC’er er knoglemarv, thymus eller perifert blod. 15
  11. 11. Fremgangsmåde ifølge krav 10, hvor kilden af humane HSC’er er knoglemarv.
  12. 12. Fremgangsmåde ifølge et hvilket som helst af kravene 9 til 11, hvor kilden af humane HSC’er og/eller cellerne er udtomt ved anvendelse af et eller flere antistoffer. 20
  13. 13. Fremgangsmåde ifølge krav 12, hvor det ene eller de flere antistoffer er konjugeret til magnetiske kom.
  14. 14. Fremgangsmåde ifølge krav 9, hvor antallet af alfa-beta-TCR+-T-celler justeres til 25 mellem 3,0 x 106 og 4,2 x 106 alfa-beta-TCR+-T-celler pr. kg af recipientens kropsvægt.
  15. 15. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 8, der kan fremstilles ved hjælp af fremgangsmåden ifølge et hvilket som helst af kravene 9 til 14. 30
DK11818739.2T 2010-08-17 2011-08-17 Humane faciliterende celler og anvendelser deraf. DK2606120T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37446010P 2010-08-17 2010-08-17
US12/957,011 US8632768B2 (en) 2008-05-30 2010-11-30 Human facilitating cells
PCT/US2011/048120 WO2012024427A2 (en) 2010-08-17 2011-08-17 Human facilitating cells and uses thereof

Publications (1)

Publication Number Publication Date
DK2606120T3 true DK2606120T3 (da) 2016-02-08

Family

ID=45605659

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11818739.2T DK2606120T3 (da) 2010-08-17 2011-08-17 Humane faciliterende celler og anvendelser deraf.

Country Status (15)

Country Link
US (3) US8632768B2 (da)
EP (2) EP3037522A1 (da)
JP (2) JP5980783B2 (da)
CN (2) CN103328627B (da)
AU (1) AU2011292011B2 (da)
CA (1) CA2807701C (da)
DK (1) DK2606120T3 (da)
ES (1) ES2561087T3 (da)
HK (1) HK1184488A1 (da)
HR (1) HRP20160102T1 (da)
HU (1) HUE028335T2 (da)
PL (1) PL2606120T3 (da)
RS (1) RS54549B1 (da)
SI (1) SI2606120T1 (da)
WO (1) WO2012024427A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US8632768B2 (en) 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
US11291686B2 (en) 2008-05-30 2022-04-05 University Of Louisville Research Foundation, Inc. Human facilitating cells
EP2686417B1 (de) * 2011-03-17 2016-06-08 Miltenyi Biotec GmbH Tcralpha/beta-depletierte zellpräparationen
EP2748307A4 (en) 2011-09-23 2015-08-19 Univ Louisville Res Found METHODS AND COMPOSITIONS FOR CELL EXPANSION AND GRAFT ENHANCEMENT
KR102109643B1 (ko) 2011-12-22 2020-05-29 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정하고 장기적인 생착을 위한 병용 치료법
US9657290B2 (en) 2012-07-03 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Scalable bio-element analysis
KR102491343B1 (ko) * 2013-02-26 2023-01-27 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 이식편의 이식 관용을 위한 합동된 장기와 조혈 세포
LT3689140T (lt) * 2014-11-24 2022-08-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmones, ekspresuojantys humanizuotą cd3 kompleksą
US10370653B2 (en) 2015-02-22 2019-08-06 The Board Of Trustees Of The Leland Stanford Junior University Micro-screening apparatus, process, and products
JP6733209B2 (ja) * 2015-03-18 2020-07-29 セイコーエプソン株式会社 シート製造装置
JP7086092B2 (ja) 2016-11-14 2022-06-17 オルカ バイオシステムズ インコーポレイテッド 標的粒子を選別する方法および装置
US20180252729A1 (en) 2017-03-06 2018-09-06 University Of Louisville Research Foundation Methods and compositions for determining the potency of a therapeutic cellular composition
AU2018234827B2 (en) 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
JP7422667B2 (ja) 2018-02-08 2024-01-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 同種造血幹細胞移植のための方法
US11273179B2 (en) 2018-03-12 2022-03-15 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10881692B2 (en) * 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) * 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US20220305057A1 (en) * 2019-06-06 2022-09-29 Medeor Therapeutics, Inc. Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells
CN116583594A (zh) * 2020-10-14 2023-08-11 奥瑟姆健康公司 用于骨髓的提取和低温保藏的系统和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
EP0652943B1 (en) * 1992-07-10 2008-07-02 University Of Pittsburgh Hematopoietic facilitatory cells and their uses
US5772994A (en) * 1993-05-28 1998-06-30 The University Of Pittsburgh Hematopoietic facilitatory cells and their uses
AU1522395A (en) * 1994-01-05 1995-08-01 University Of Pittsburgh Monoclonal antibodies to antigens expressed by hematopoietic facilitatory cells
AU1705599A (en) 1997-11-26 1999-06-15 Allegheny University Of The Health Sciences Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
AU2002220031A1 (en) * 2000-11-14 2002-05-27 The University Of Louisville Research Foundation, Inc. Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
US20040228845A1 (en) * 2003-05-14 2004-11-18 Ildstad Suzanne T. Methods of using CD8+/TCR- facilitating cells (FC) for the engraftment of purified hematopoietic stem cells (HSC)
WO2002089746A2 (en) * 2001-05-09 2002-11-14 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
US20050118142A1 (en) * 2001-08-01 2005-06-02 Ildstad Suzanne T. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
WO2005023982A2 (en) 2003-05-28 2005-03-17 Univ. Of Louisville Research Foundation, Inc. Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients
US8632768B2 (en) 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
CA2726341C (en) * 2008-05-30 2018-12-18 University Of Louisville Research Foundation, Inc. Human facilitating cells

Also Published As

Publication number Publication date
US20170000825A1 (en) 2017-01-05
US20110110909A1 (en) 2011-05-12
CA2807701C (en) 2023-12-19
WO2012024427A2 (en) 2012-02-23
AU2011292011B2 (en) 2015-08-13
JP5980783B2 (ja) 2016-08-31
CN105950556A (zh) 2016-09-21
ES2561087T3 (es) 2016-02-24
CN103328627A (zh) 2013-09-25
EP2606120B1 (en) 2015-10-28
CA2807701A1 (en) 2012-02-23
US8632768B2 (en) 2014-01-21
RS54549B1 (en) 2016-06-30
JP2013535230A (ja) 2013-09-12
PL2606120T4 (pl) 2016-06-30
JP2016190866A (ja) 2016-11-10
CN103328627B (zh) 2016-06-01
US20140134141A1 (en) 2014-05-15
SI2606120T1 (sl) 2016-03-31
HUE028335T2 (en) 2016-12-28
EP2606120A4 (en) 2014-03-26
CN105950556B (zh) 2021-12-03
US9452184B2 (en) 2016-09-27
AU2011292011A1 (en) 2013-02-21
WO2012024427A3 (en) 2012-05-10
EP2606120A2 (en) 2013-06-26
PL2606120T3 (pl) 2016-06-30
HK1184488A1 (en) 2014-01-24
HRP20160102T1 (hr) 2016-02-26
JP6449199B2 (ja) 2019-01-09
EP3037522A1 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
DK2606120T3 (da) Humane faciliterende celler og anvendelser deraf.
Wagner et al. Cell-mediated immune response in vitro: II. The role of thymus and thymus-derived lymphocytes
JP7483087B2 (ja) 造血幹細胞移植用の組成物および方法
US20050118142A1 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
CA2726341C (en) Human facilitating cells
US20220202854A1 (en) Human facilitating cells
US20230226115A1 (en) Human facilitating cells
AU2015252158A1 (en) Human facilitating cells and uses thereof
CN112135901A (zh) 获得源自胸腺组织的调节性t细胞的方法及所述细胞作为细胞免疫疗法在免疫系统失调中的用途
AU2015213389A1 (en) Human facilitating cells